Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEDI8852 + oseltamivir
- Development stage
- Unknown
- Lead developer
- MedImmune
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
**MEDI8852 + oseltamivir** is a combination therapy evaluated for the treatment of acute, uncomplicated influenza A infection in adults. MEDI8852 is a human IgG1 kappa monoclonal antibody that broadly targets the hemagglutinin (HA) stem region of influenza A viruses, inhibiting viral entry and fusion. Oseltamivir is a small-molecule neuraminidase inhibitor that prevents the release of new virions from infected cells. This combination is investigated to determine whether joint administration provides improved safety or efficacy compared to either agent alone. Clinical studies have shown the combination to be generally well tolerated, but with no significant additional clinical benefit over monotherapy in uncomplicated influenza A infection[1][4].
- Other names
- MEDI8852 + Tamiflu
02
Targets
HA stem (Influenza A hemagglutinin stem region)Neuraminidase
Beyond the preview
Go deeper on MEDI8852 + oseltamivir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEDI8852 + oseltamivir.